Protheragen-ING Lab Launches Comprehensive Pharmaceutical Safety Evaluation Services

Protheragen-ING Lab, a trustworthy GLP service provider, today announced its latest suite of pharmaceutical safety evaluation services. This is a huge development in the drug development landscape and the company uses its ISO9001 certified infrastructure to follow internationally accepted standards for pre-clinical safety testing.

Thanks to innovation and need for safer, more effective drugs, the pharmaceutical sector is always changing. The new safety evaluation services that Protheragen-ING Lab is offering aim to fill important information gaps during the drug development process without having to tread into clinical treatment and patient care areas. Services are specifically designed to support researchers, and they provide all the technical analyses that are critical to understanding whether a candidate drug is safe or effective.

Underlying all these reviews are exhaustive reports covering many important points of importance to drug safety. Protheragen-ING Lab offers ADME (Absorption, Distribution, Metabolism, and Excretion) testing, the foundation for knowing how a drug behaves in the body. These studies are essential to the explanation of interactions and the pharmacokinetics of novel drug candidates.

General toxicology studies add to these analyses with acute, sub-chronic and chronic toxicity, as well as carcinogenicity. Toxicity analyses like these are a necessity for determining potential adverse effects across multiple organ systems. Genetic toxicology testing is also used to make sure that drug candidates don’t damage or mutation DNA, protecting the genetic quality of future drugs.

Safety pharmacology studies add to the service offering, by analysing the effects of drug compounds on important organ systems such as the cardiovascular and respiratory structures. These are used in conjunction with immunotoxicology testing to identify any immunosuppressive or immunostimulatory effects — important to ensure a healthy immune response.

For PK/PD pharmacokinetics and PD pharmacodynamics, Protheragen-ING Lab helps to get a comprehensive picture of how the drug is absorbed, distributed and excreted for best dosing. PD tests, by contrast, give us an idea of how drugs work on their target receptors and in general on the body.

That kind of resolute approach ensures that researchers equipped with Protheragen-ING Lab’s support will overcome early development roadblocks. In the process of discovering risks in the early stages, the company helps build quality medications without compromising safety.

“Our staff are highly experienced researchers. Our company, as a whole, drives an ethic of scientific rigorousness, conformance and timely execution – the assurance to customers that superior support is in place from early evaluation to the end of commercial drug development,” said the Marketing Chief of Protheragen-ING Lab.

About Protheragen-ING

With a team of highly skilled scientists and technicians, Protheragen-ING Lab, a branch of Protheragen-ING, is committed to providing clients with accurate and reliable results that meet the highest quality standards. By offering a comprehensive range of lab synthesis and testing services such as pharmaceutical stability testing and drug impurity testing, Protheragen-ING Lab is helping companies to navigate the complex regulatory landscape and bring safe and effective products to market.